美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

博科

12.73

0.0000

成交量：- -

成交額：- -

市值：52.68億

市盈率：45.46

高：12.73

開：12.73

低：12.73

收：12.73

52周最高：12.74

52周最低：11.43

股本：4.14億

流通股本：4.01億

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.2800

淨資產收益率：--

總資產收益率：--

市淨率：2.08

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

證監會同意泰諾麥博科創板IPO註冊

泰諾麥博科創板IPO提交註冊致力於血液製品替代療法的創新生物製藥企業

泰諾麥博科創板IPO通過上市委會議核心產品斯泰度塔單抗注射液已在中國獲批上市

智通财经网

阿斯利康蘇博科：中國在技術發展領域處於領先地位

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BRCD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRCD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRCD\",,,,,undefined,":{"symbol":"BRCD","market":"US","secType":"STK","nameCN":"博科","latestPrice":12.73,"timestamp":1575666000000,"preClose":12.73,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":400870000,"shares":413816000,"eps":0.28,"marketStatus":"退市","change":0,"latestTime":"12-06 16:00:00 EST","open":12.73,"high":12.73,"low":12.73,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.28,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1785484800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.73,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRCD\",,,,,undefined,":{"symbol":"BRCD","floatShares":400870000,"roa":"--","roe":"--","lyrEps":0,"shares":413816000,"dividePrice":0,"high":12.73,"amplitude":0,"preClose":12.73,"low":12.73,"week52Low":11.43,"pbRate":"2.08","week52High":12.74,"institutionHeld":0.8165,"latestPrice":12.73,"eps":0.28,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.28,"open":12.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRCD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-09-08","symbol":"BRCD","amount":0.055,"name":"博科","currency":"USD","type":"dividend","dateTimestamp":1504843200000},{"market":"US","date":"2017-08-24","symbol":"BRCD","fiscalQuarterEnding":"2017/07","expectedEps":0.04,"name":null,"time":"盤後","type":"earning","dateTimestamp":1503547200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2017-06-08","symbol":"BRCD","amount":0.055,"name":"博科","currency":"USD","type":"dividend","dateTimestamp":1496894400000},{"market":"US","date":"2017-05-25","symbol":"BRCD","fiscalQuarterEnding":"2017/04","expectedEps":0.01,"name":null,"time":"盤後","type":"earning","dateTimestamp":1495684800000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2017-03-08","symbol":"BRCD","amount":0.055,"name":"博科","currency":"USD","type":"dividend","dateTimestamp":1488949200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRCD\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-08","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2017-06-08","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2017-09-08","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRCD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRCD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640155809","title":"證監會同意泰諾麥博科創板IPO註冊","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155809","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640155809?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 16:59","pubTimestamp":1780563593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月4日，中国证监会发布《关于同意珠海泰诺麦博制药股份有限公司首次公开发行股票注册的批复》。据悉，泰诺麦博拟在上交所科创板上市，华泰联合证券为其保荐机构，拟募资15亿元。据招股书，公司成立于2015年，是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BRCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638588014","title":"泰諾麥博科創板IPO提交註冊 致力於血液製品替代療法的創新生物製藥企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2638588014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638588014?lang=zh_tw&edition=fundamental","pubTime":"2026-05-25 07:08","pubTimestamp":1779664101,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月22日，珠海泰诺麦博制药股份有限公司申请上交所科创板IPO审核状态变更为“提交注册”。据招股书，公司成立于2015年，是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。公司以“创造临床价值”为导向，秉持差异化创新和竞争战略，致力于全人源单抗新药的开发、制造、商业化及全球特异性血液制品的潜在替代，以满足广泛的临床需求，造福病患。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BRCD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657568","title":"泰諾麥博科創板IPO通過上市委會議 核心產品斯泰度塔單抗注射液已在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657568","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657568?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 20:07","pubTimestamp":1775218078,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月3日，珠海泰诺麦博制药股份有限公司通过上交所科创板上市委会议。招股书显示，泰诺麦博是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。其中：公司核心产品斯泰度塔单抗注射液于 2025年2月在中国获批上市，为全球同类首创的重组抗破伤风毒素单克隆抗体药物，被中国 CDE 认定为突破性治疗药物并纳入优先审评程序、被美国 FDA 纳入快速通道资格，在破伤风预防领域具有全球领先的革新性意义。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SPCX","SPCK","BRCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621726134","title":"阿斯利康蘇博科：中國在技術發展領域處於領先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2621726134","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621726134?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 11:18","pubTimestamp":1774235880,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京举行。在“健康中国2030”与大健康产业发展专题研讨会上，阿斯利康全球首席执行官苏博科强调，中国在技术发展领域处于领先地位，未来几年将在全球医疗健康行业发挥更重要作用：目前全球25%的临床试验在中国开展，30%的全球行业价值流向中国，而10年前这一比例仅为1%，充分彰显了中国在全球医疗领域的重要影响力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtx8052868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0889565916.HKD","LU2236285917.USD","LU0289739699.SGD","LU0109394709.USD","LU0320765992.SGD","BK4585","BRCD","LU0058720904.USD","LU2417539215.USD","BK4588","BK4568","LU2462157665.USD","LU2456880835.USD","LU1829250122.USD","AZN","IE00B3T34201.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BRCD\",params:#limit:6,delay:false,,,undefined,":[]}}